No Association Between Decreases in Serum Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) and Serious Infections (SI) with Long-term Ublituximab (UBL) Treatment in Patients with Relapsing Multiple Sclerosis (RMS) (P7-1.017)
Authors
Hari P. Miskin
Krzysztof Selmaj (ORCID: https://orcid.org/0000-0003-1213-7218)
No Association Between Decreases in Serum Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) and Serious Infections (SI) with Long-term Ublituximab (UBL) Treatment in Patients with Relapsing Multiple Sclerosis (RMS) (P7-1.017)
Hari P. Miskin, Krzysztof Selmaj, Derrick Robertson, Enrique Álvarez et al.
Local Database Links
1 links
Journal
Neurology
Topics
Multiple Sclerosis Research Studies
article
No Association Between Decreases in Serum Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) and Serious Infections (SI) with Long-term Ublituximab (UBL) Treatment in Patients with Relapsing Multiple Sclerosis (RMS) (P7-1.017)
Hari P. Miskin, Krzysztof Selmaj, Derrick Robertson, Enrique Álvarez, Daniel Wynn, Lawrence Steinman, Jackie Parker, Karthik Bodhinathan, Peter Sportelli, Bruce Cree, Christopher R. Rowland, Koby Mok, Peiqing Qian, Edward Fox, Yanzhi Hsu, Hans Hartung, Sibyl Wray, Yihuan Xu
article en
Abstract
No abstract available for this paper.
Publication Tag
NeurologyVol. 104(7_Supplement_1)
Institutions
University of South Florida (US), Multiple Sclerosis Foundation (US), University of Colorado System (US), HOPE Clinic (US), Stanford Medicine (US), CDG Therapeutics (United States) (US), Heinrich Heine University Düsseldorf (DE), University of Warmia and Mazury in Olsztyn (PL)